Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide

Acta Pharmacologica Sinica

Volumn 28, Issue 11, 2007, Pages 1842-1850

  Huang, Mao Tao ^a   Chen, Zhi Xin ^a   Wei, Bing ^a   Zhang, Bo ^a   Wang, Chun Hui ^a   Huang, Ming Hui ^a   Liu, Rui ^a   Tang, Cheng Wei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Celecoxib; Gastric adenocarcinoma; Non cytotoxic agent; Octreotide; Surgery

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CELECOXIB; CYCLOOXYGENASE 2; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DNA NUCLEOTIDYLEXOTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; SOMATOSTATIN RECEPTOR 2;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG FEVER; FEMALE; GASTRECTOMY; GASTROINTESTINAL HEMORRHAGE; GENE ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; NICK END LABELING; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; STOMACH ADENOCARCINOMA; TISSUE NECROSIS; TUMOR CELL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PYRAZOLES; RECEPTORS, SOMATOSTATIN; STOMACH NEOPLASMS; SULFONAMIDES;

EID: 35648976650     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00652.x     Document Type: Article

References (30)

1. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005 241 : 27 39.
2. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004 15 : 1585 95.
3. Liu CL, Tang CW, Wang CH, Zhou XC. The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adeno-carcinoma. J West China Univ Med Sci 2003 3 : 372 5. Chinese.
4. Baek SJ, Wilson LC, Lee CH, Eling TE. Dual function of nonste-roidal anti-inflammatory drugs (NSAIDs): inhibition of cyclo-oxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002 301 : 1126 31.
5. Uefuji K, Ichikura T, Mochizuki H. Expression of cyclo-oxyge-nase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001 76 : 26 30.
6. Ohno R, Yoshinaga K, Fujita T, Hasegawa K, Iseki H, Tsunozaki H, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001 91 : 1876 81.
7. Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 1999 80 : 448 54.
8. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998 217 : 143 52.
9. Tang C, Wang C, Tang L. Effects of combined octreotide and aspirin on the growth of gastric cancer. Chin Med J (Engl) 2003 116 : 373 7.
10. Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, et al. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer 1994 57 : 574 80.
11. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995 16 : 427 42.
12. Kwon KS, Chae HJ. Sodium salicylate inhibits expression of COX-2 through suppression of ERK and subsequent NF-kappaB activation in rat ventricular cardiomyocytes. Arch Pharm Res 2003 26 : 545 53.
13. Tang CW, Liu CL, Zhou XC, Wang CH. Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Int J Cancer 2004 112 : 470 4.
14. Gavrieli Y, Sherman Y, Beb-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992 119 : 493 501.
15. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002 86 : 1566 77.
16. Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, et al. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res 2005 11 : 6472 8.
17. Casper D, Bukhtiyarova M, Springman EB. A Biacore biosensor method for detailed kinetic binding analysis of small molecule inhibitors of p38alpha mitogen-activated protein kinase. Anal Biochem 2004 325 : 126 36.
18. Sarbia M, Becker KF, Hofler H. Pathology of upper gastrointestinal malignancies. Semin Oncol 2004 31 : 465 75.
19. Jazowiecka-Rakus J, Jarosz M, Kozlowska D, Sochanik A, Szala S. Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors. Acta Biochim Pol 2007 54 : 125 33.
20. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998 1 : 10 24.
21. Diasio RB, Fourie J. Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs 2006 66 : 1441 63.
22. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005 67 : 356 64.
23. Hu C, Yi C, Hao Z, Cao S, Li H, Shao X, et al. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol Ther 2004 3 : 726 30.
24. Kouroumalis EA. Octreotide for cancer of the liver and biliary tree. Chemotherapy 2001 47 Suppl 2 : 150 61.
25. Wang CH, Tang CW, Liu CL, Tang LP. Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway. World J Gastroenterol 2003 9 : 1904 8.
26. Liu C, Tang C, Zhou X, Wang C. Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Basic Med Sci Clin 2004 24 : 277 81. Chinese.
27. Gajraj NM. Cyclooxygenase-2 inhibitors. Anesth Analg 2003 96 : 1720 38.
28. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001 296 : 558 66.
29. Macdonald JS. Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 2004 54 Suppl 1 : S4 11.
30. Lindsey H. Preoperative chemoradiotherapy shows promise in gastric cancer. Lancet Oncol 2004 5 : 519.